Market revenue in 2021 | USD 12.6 million |
Market revenue in 2032 | USD 79.4 million |
Growth rate | 18.2% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 30.95% in 2021. Horizon Databook has segmented the Middle East & Africa myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
The growth of Middle East and Africa (MEA) myasthenia gravis treatment market can be attributed to continuous government initiatives to enable early diagnosis and quality treatment of MG in the region.
Furthermore, increasing risk of MG due to high prevalence of HIV in countries such as South Africa is expected to create high demand for its treatment therapies.
However, low awareness about diseases, uncertain reimbursement scenarios, and lack of skilled professionals in some countries of MEA are among factors expected to be a major threat to market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa myasthenia gravis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account